BLRXBioLineRx, Ltd.Running, no new patients
A Phase III, Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and Granulocyte Colony Stimulating Factor (G-CSF) as Compared to Placebo and G-CSF for the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Subjects With Multiple Myeloma (MM)
Multiple Myeloma
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 180 (final count)
- Started
- Mar 23, 2018
- Main results expected
- Dec 22, 2020
- Fully finished
- Sep 30, 2029
- Results posted
- Nov 7, 2023
What counts as success
The trial's main goal(s), called the “primary outcome.”
Percentage of Subjects Mobilizing ≥6 × 10^6 CD34+ Cells/kg With up to 2 Apheresis Sessions
Measured over: From first day of study treatment (G-CSF) until day of second apheresis which was planned to occur on Day 6
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT03246529 · record last updated 2026-01-15 · checked 2026-11-09 15:47 UTC